# Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

Source: https://onco.cc/trials/nct06745908/  
OnCo record `nct06745908` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nogapendekin alfa inbakicept, Tislelizumab and Docetaxel in non-small-cell lung cancer, run by ImmunityBio, Inc., now recruiting.

## Summary

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In is a phase 3 interventional study registered as NCT06745908 by ImmunityBio, Inc., with 507 participants planned, started 2025-10-01 and due to reach its primary completion in 2028-09. Interventions recorded: N-803, Tislelizumab, Docetaxel and Prior failed checkpoint inhibitor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06745908
- Phase: 3
- Setting: Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Sponsor: ImmunityBio, Inc.
- Enrolled: 507

## Sources

- ClinicalTrials.gov NCT06745908: https://clinicaltrials.gov/study/NCT06745908

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Nogapendekin alfa inbakicept](https://onco.cc/drugs/nogapendekin-alfa/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [ImmunityBio](https://onco.cc/companies/immunitybio/)

---
JSON: https://onco.cc/api/v1/entities/nct06745908.json